Is Vir Biotechnology Stock a Good Investment?
Vir Biotechnology Investment Advice | VIR |
- Examine Vir Biotechnology's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Vir Biotechnology's leadership team and their track record. Good management can help Vir Biotechnology navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Vir Biotechnology's business and its evolving consumer preferences.
- Compare Vir Biotechnology's performance and market position to its competitors. Analyze how Vir Biotechnology is positioned in terms of product offerings, innovation, and market share.
- Check if Vir Biotechnology pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Vir Biotechnology's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Vir Biotechnology stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Vir Biotechnology is a good investment.
Sell | Buy |
Hold
Market Performance | OK | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Vir Biotechnology Stock
Researching Vir Biotechnology's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 76.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 1.07. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Vir Biotechnology has Price/Earnings To Growth (PEG) ratio of 1.14. The entity recorded a loss per share of 3.93. The firm had not issued any dividends in recent years.
To determine if Vir Biotechnology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Vir Biotechnology's research are outlined below:
| Vir Biotechnology is way too risky over 90 days horizon | |
| Vir Biotechnology appears to be risky and price may revert if volatility continues | |
| The company reported the last year's revenue of 86.18 M. Reported Net Loss for the year was (615.06 M) with loss before taxes, overhead, and interest of (416.93 M). | |
| Vir Biotechnology has about 2.2 B in cash with (778.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.55, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Vir Biotechnology has a frail financial position based on the latest SEC disclosures | |
| Over 76.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 1562 shares by Brent Sabatini of Vir Biotechnology at 9.1494 subject to Rule 16b-3 |
Vir Biotechnology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Vir Biotechnology. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Vir Biotechnology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Vir Biotechnology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Vir Biotechnology's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-11-10 | 2020-09-30 | -0.6 | -0.67 | -0.07 | 11 | ||
2024-08-01 | 2024-06-30 | -0.9 | -1.02 | -0.12 | 13 | ||
2021-02-25 | 2020-12-31 | -0.7 | -0.83 | -0.13 | 18 | ||
2024-02-22 | 2023-12-31 | -1.01 | -0.86 | 0.15 | 14 | ||
2020-05-12 | 2020-03-31 | -0.53 | -0.71 | -0.18 | 33 | ||
2023-05-04 | 2023-03-31 | -0.87 | -1.06 | -0.19 | 21 | ||
2023-08-03 | 2023-06-30 | -1.2 | -1.45 | -0.25 | 20 | ||
2020-08-11 | 2020-06-30 | -0.62 | -0.27 | 0.35 | 56 |
Know Vir Biotechnology's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Vir Biotechnology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vir Biotechnology backward and forwards among themselves. Vir Biotechnology's institutional investor refers to the entity that pools money to purchase Vir Biotechnology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Renaissance Technologies Corp | 2024-09-30 | 1.2 M | Millennium Management Llc | 2024-09-30 | 1.1 M | Jefferies Financial Group Inc | 2024-09-30 | 1.1 M | Voloridge Investment Management, Llc | 2024-09-30 | 975.3 K | D. E. Shaw & Co Lp | 2024-09-30 | 930.7 K | Northern Trust Corp | 2024-09-30 | 878.9 K | Goldman Sachs Group Inc | 2024-09-30 | 832.7 K | Bank Of New York Mellon Corp | 2024-12-31 | 604.1 K | Barclays Plc | 2024-09-30 | 550.2 K | Sb Investment Advisers (uk) Ltd | 2024-09-30 | 16.7 M | Blackrock Inc | 2024-09-30 | 16.4 M |
Vir Biotechnology's market capitalization trends
The company currently falls under 'Mid-Cap' category with a total capitalization of 1.33 B.Market Cap |
|
Vir Biotechnology's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.29) | (0.31) | |
| Return On Capital Employed | (0.35) | (0.37) | |
| Return On Assets | (0.29) | (0.30) | |
| Return On Equity | (0.44) | (0.42) |
Determining Vir Biotechnology's profitability involves analyzing its financial statements and using various financial metrics to determine if Vir Biotechnology is a good buy. For example, gross profit margin measures Vir Biotechnology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Vir Biotechnology's profitability and make more informed investment decisions.
Evaluate Vir Biotechnology's management efficiency
Vir Biotechnology has Return on Asset of (0.1941) % which means that on every $100 spent on assets, it lost $0.1941. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.3658) %, meaning that it generated no profit with money invested by stockholders. Vir Biotechnology's management efficiency ratios could be used to measure how well Vir Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. As of 02/16/2025, Return On Tangible Assets is likely to drop to -0.31. In addition to that, Return On Capital Employed is likely to drop to -0.37. At this time, Vir Biotechnology's Net Tangible Assets are relatively stable compared to the past year. As of 02/16/2025, Non Currrent Assets Other is likely to grow to about 17.8 M, while Non Current Assets Total are likely to drop slightly above 219 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 10.67 | 11.20 | |
| Tangible Book Value Per Share | 10.41 | 10.93 | |
| Enterprise Value Over EBITDA | (1.67) | (1.75) | |
| Price Book Value Ratio | 0.76 | 0.80 | |
| Enterprise Value Multiple | (1.67) | (1.75) | |
| Price Fair Value | 0.76 | 0.80 | |
| Enterprise Value | 1.1 B | 1.8 B |
The operational strategies employed by Vir Biotechnology management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Beta 0.632 |
Basic technical analysis of Vir Stock
As of the 16th of February 2025, Vir Biotechnology has the Coefficient Of Variation of 2880.86, semi deviation of 4.91, and Risk Adjusted Performance of 0.0337. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vir Biotechnology, as well as the relationship between them. Please validate Vir Biotechnology jensen alpha and semi variance to decide if Vir Biotechnology is priced more or less accurately, providing market reflects its prevalent price of 9.65 per share. Given that Vir Biotechnology has jensen alpha of 0.2818, we advise you to double-check Vir Biotechnology's current market performance to make sure the company can sustain itself at a future point.Vir Biotechnology's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vir Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vir Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vir Biotechnology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Vir Biotechnology's Outstanding Corporate Bonds
Vir Biotechnology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Vir Biotechnology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Vir bonds can be classified according to their maturity, which is the date when Vir Biotechnology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Virgin Media Communications Corp BondUS92769VAJ89 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Viper Energy Partners Corp BondUS92763MAA36 | View | |
| Virgin Media 55 Corp BondUS92769XAP06 | View | |
| Virgin Media Investment Corp BondUS92769XAR61 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand Vir Biotechnology's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Vir Biotechnology's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0337 | |||
| Market Risk Adjusted Performance | 0.1564 | |||
| Mean Deviation | 4.26 | |||
| Semi Deviation | 4.91 | |||
| Downside Deviation | 5.35 | |||
| Coefficient Of Variation | 2880.86 | |||
| Standard Deviation | 8.47 | |||
| Variance | 71.71 | |||
| Information Ratio | 0.0334 | |||
| Jensen Alpha | 0.2818 | |||
| Total Risk Alpha | 0.2707 | |||
| Sortino Ratio | 0.0529 | |||
| Treynor Ratio | 0.1464 | |||
| Maximum Drawdown | 71.23 | |||
| Value At Risk | (7.29) | |||
| Potential Upside | 6.0 | |||
| Downside Variance | 28.59 | |||
| Semi Variance | 24.09 | |||
| Expected Short fall | (4.42) | |||
| Skewness | 4.94 | |||
| Kurtosis | 34.03 |
| Risk Adjusted Performance | 0.0337 | |||
| Market Risk Adjusted Performance | 0.1564 | |||
| Mean Deviation | 4.26 | |||
| Semi Deviation | 4.91 | |||
| Downside Deviation | 5.35 | |||
| Coefficient Of Variation | 2880.86 | |||
| Standard Deviation | 8.47 | |||
| Variance | 71.71 | |||
| Information Ratio | 0.0334 | |||
| Jensen Alpha | 0.2818 | |||
| Total Risk Alpha | 0.2707 | |||
| Sortino Ratio | 0.0529 | |||
| Treynor Ratio | 0.1464 | |||
| Maximum Drawdown | 71.23 | |||
| Value At Risk | (7.29) | |||
| Potential Upside | 6.0 | |||
| Downside Variance | 28.59 | |||
| Semi Variance | 24.09 | |||
| Expected Short fall | (4.42) | |||
| Skewness | 4.94 | |||
| Kurtosis | 34.03 |
Consider Vir Biotechnology's intraday indicators
Vir Biotechnology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Vir Biotechnology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Vir Biotechnology Corporate Filings
F4 | 14th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 30th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 4th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
13A | 18th of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
Vir Stock media impact
Far too much social signal, news, headlines, and media speculation about Vir Biotechnology that are available to investors today. That information is available publicly through Vir media outlets and privately through word of mouth or via Vir internal channels. However, regardless of the origin, that massive amount of Vir data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Vir Biotechnology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Vir Biotechnology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Vir Biotechnology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Vir Biotechnology alpha.
Vir Biotechnology Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Vir Biotechnology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
I See a Vir-y Good Trade
recently @ finance.yahoo.com
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Vir Biotechnology Corporate Management
| Vanina JD | General VP | Profile | |
| Klaus Frueh | CoFounder Advisor | Profile | |
| Lawrence MD | CoFounder Advisor | Profile | |
| Johanna FriedlNaderer | Ex COO | Profile | |
| George Scangos | CEO Pres | Profile | |
| Louis MD | CoFounder Advisor | Profile |
Additional Tools for Vir Stock Analysis
When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.